Publications scientifiques sur les diagnostics non invasifs BioPredictive
Études évaluées par les pairs validant les diagnostics sanguins BioPredictive pour les maladies du foie — des cohortes pionnières aux méta-analyses à long terme.
29/436
Résultats pour
“uncertainty”
-
Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Key publication
…An unmet need is to reduce the uncertainty of biomarkers for the…
-
Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes. Key publication
### Background One of the unmet needs in patients with type 2 diabetes…
-
An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.
**Background:** The current definition of metabolic dysfunction-associated steatotic liver disease (MASLD…
-
An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis.
…In uncertainty analyses in which biopsy sampling error was considered, the Fibrosure…
-
Pilon A, Vaubourdolle M, Peta V, Valla D, Castera L, Bedossa P, Ratziu V, Deckmyn O, Poynard T; the QuidNash Consortium Key publication
-
Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.
### Background Excessive alcohol consumption may lead to the development of alcohol-related…
-
Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".
### Background The aspartate aminotransferase platelet ratio index (APRI) is a validated, non…
-
Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection.
### Objectives Staging liver fibrosis in chronic viral hepatitis C (HCV) patients is…
-
Predicting significant fibrosis in hepatitis C patients in Luxembourg using serological markers.
### Objective The aim of our study was to assess the diagnostic performance…
-
Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis. Review
### Background Liver fibrosis is a sign of advanced liver disease and is…
-
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.
-
EASL clinical practical guidelines: management of alcoholic liver disease.
-
Effective use of FibroTest to generate decision trees in hepatitis C.
### Aim To assess the usefulness of FibroTest to forecast scores by constructing…
-
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.
-
The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis.
### Background And Aims Blood tests and liver stiffness evaluation (LSE) by ultrasonographic…
-
Impact of quality control accepted inter-laboratory variations on calculated Fibrotest/Actitest scores for the non-invasive biochemical assessment of liver fibrosis.
### Introduction Non-invasive, i.e. serum-based assessment of liver fibrosis is…
-
EASL Clinical Practice Guidelines: management of hepatitis C virus infection.
-
Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.
### Introduction A prognostic model to predict liver severity in people with metabolic…
-
Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies.
Noninvasive indexes have been developed to predict fibrosis staging. The aim of…
-
Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.
As of 2016, there is no evidence-based pathway to stratify the…
-
Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study.
### Objective Screening for advanced fibrosis (AF) resulting from metabolic dysfunction-associated steatotic…
-
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. Key publication
### Background & Aims The Liver Cancer Risk test algorithm (LCR1-LCR2) is a…
-
Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.
### Background And Aim Mortality of alcohol-related liver disease (ArLD) is increasing…
-
Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review
Even though alcohol-related liver disease (ALD) is a major cause of…
-
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication
-
FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. Meta Analysis
### Objectives Extent of liver fibrosis is one of the most important factors…
-
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
-
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.
### Background Many blood tests have been proposed as alternatives to liver biopsy…
-
Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection
These are the first World Health Organization (WHO) guidelines for the prevention…
Affichage de la liste complète des résultats. La page est rendue côté serveur et non paginée.